Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) announced that its partner STADA Arzneimittel AG's subsidiary, Spirig HealthCare AG, has received approval from the Swiss Medicines Agency for the marketing authorization of tofacitinib citrate tablets, marking a significant milestone in the treatment of autoimmune diseases [1] Group 1 - Tofacitinib citrate tablets are the world's first approved oral Janus kinase (JAK) inhibitor, classified as a targeted synthetic disease-modifying antirheumatic drug (DMARD) [1] - The drug works by inhibiting the intracellular JAK signaling pathway, which regulates immune responses [1] - It is primarily used for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, among other autoimmune diseases [1]

Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) announced that its partner STADA Arzneimittel AG's subsidiary, Spirig HealthCare AG, has received approval from the Swiss Medicines Agency for the marketing authorization of tofacitinib citrate tablets, marking a significant milestone in the treatment of autoimmune diseases [1] Group 1 - Tofacitinib citrate tablets are the world's first approved oral Janus kinase (JAK) inhibitor, classified as a targeted synthetic disease-modifying antirheumatic drug (DMARD) [1] - The drug works by inhibiting the intracellular JAK signaling pathway, thereby modulating immune responses [1] - It is primarily used for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, which are all autoimmune diseases [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) and its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. have received drug registration certificates from the National Medical Products Administration for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) [1] Group 1: Drug Approvals - The company has obtained approval for Dydrogesterone, a synthetic progestogen used for treating diseases caused by endogenous progesterone deficiency and for luteal support in assisted reproductive technology [1] - Baricitinib is a Janus kinase (JAK) inhibitor that blocks the activity of one or more members of the JAK kinase family, thereby inhibiting pathways that activate inflammation, developed in collaboration with Eli Lilly and Incyte [1] - Dapagliflozin is indicated for the treatment of type 2 diabetes [1]

Core Viewpoint - The company TianKang (301263.SZ) has received a drug registration certificate for Baricitinib tablets from the National Medical Products Administration, indicating a significant regulatory milestone for the company in the pharmaceutical sector [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has been granted the drug registration certificate for Baricitinib tablets [1] - Baricitinib is identified as a Janus kinase (JAK) inhibitor, which can block the activity of one or more members of the JAK kinase family, thereby inhibiting pathways that activate inflammation [1]